# Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

> **NCT00002947** · PHASE1 · TERMINATED · sponsor: **Yale University** · enrollment: 35 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors
- Childhood Langerhans Cell Histiocytosis
- Gastrointestinal Carcinoid Tumor
- Head and Neck Cancer
- Intraocular Melanoma
- Islet Cell Tumor
- Kidney Cancer
- Lung Cancer
- Melanoma (Skin)
- Neoplastic Syndrome
- Neuroendocrine Carcinoma of the Skin
- Pheochromocytoma

## Interventions

- **RADIATION:** indium In 111 pentetreotide

## Key facts

- **NCT ID:** NCT00002947
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-10
- **Primary completion:** 2004-08
- **Final completion:** 2004-08
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2014-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002947, "Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00002947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*